Specifically, Merck has been collaborating with Ridgeback Biotherapeutics on a clinical development program for molnupiravir, an oral antiviral medication. Management is hoping this partnership will finally pay off in the form of an outpatient COVID-19 treatment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,